Abstract
Myasthenia gravis (MG) is an autoimmune disease associated with antibodies directed to the postsynaptic muscle components of the neuromuscular junction. The heterogeneous nature of the acetylcholine receptor (AChR) antibody response had led to the categorization of AChR antibodies into 3 types: binding, blocking, and modulating antibodies. The purpose of this study is to compare the AChR antibodies’ type with the clinical severity of MG patients. The patients enrolled in the study had been tested for both binding and blocking antibodies and had disease duration exceeding 2 years since diagnosis. The patients were divided into five main classes by the Myasthenia Gravis Foundation of America clinical classification. Again, the enrolled patients were divided into ocular and generalized group. We compared the type and titer of antibodies and the thymus status between the ocular and generalized group. Thirty-five patients met the inclusion criteria. Of these, 16 patients (47 %) had both blocking and binding AChR antibodies, 11 patients (31 %) had only binding antibodies, and 8 patients (22 %) had only blocking antibodies. By defined clinical classification, the ocular and generalized groups included 10 and 25 patients, respectively. Sixteen patients in the generalized group possessed both AChR antibodies, with the remaining patients displaying only the binding antibody. All the patients with only blocking antibody were classified into ocular group. Use of binding and blocking antibodies’ tests may, therefore, be more helpful in predicting the prognosis and diagnoses of MG patient.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Patrick J, Lindstrom J (1973) Autoimmune response to acetylcholine receptors. Science 180:871–872
Bates MD, Stassen MHW (2002) The role of antibodies in myasthenia gravis. J Neurol Sci 202:5–11
Hoch W, McConville J, Helms S et al (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365–368
Higuchi O, Hamuro J, Motomura M et al (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69:418–422
Zhang B, Tzartos JS, Belimezi M et al (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69:445–451
Lennon VA (1997) Serologic profile of myasthenia gravis and distinction from the Lambert–Eaton syndrome. Neurology 48:S23–S27
Drachman DB, Adams RN, Stanley EF et al (1980) Mechanisms of acetylcholine receptor loss in myasthenia gravis. J Neurol Neurosurg Psychiatry 43:601–610
Howard FM Jr, Lennon VA, Finley J et al (1987) Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann NY Acad Sci 505:526–538
Pachner AR (1989) Anti-acetylcholine receptor antibodies block bungarotoxin binding to native human acetylcholine receptor on the surface of TE671 cells. Neurology 39:1057–1061
Keesey JC (2004) Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29:484–505
Lefvert AK, Bergstrom K, Matell G et al (1978) Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenic implications. J Neurol Neurosurg Psychiatry 41:394–403
Lindstrom JM, Seybold ME, Lennon VA et al (1976) Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 26:1054–1059
Nicholson GA, McLeod JG, Griffiths LR (1983) Comparison of diagnostic tests in myasthenia gravis. Clin Exp Neurol 19:45–49
Benatar M (2006) A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 16:459–467
Tindall RS (1981) Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol 10:437–447
Vincent A, Newsom Davis J (1980) Anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry 43:590–600
Besinger UA, Toyka KV, Hömberg M et al (1983) Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33:1316–1321
Yu YL, Hawkins BR, Ip MS et al (1992) Myasthenia gravis in Hong Kong Chinese. 1. Epidemiology and adult disease. Acta Neurol Scand 86:113–119
Lindstrom JM (2000) Acetylcholine receptors and myasthenia. Muscle Nerve 23:453–477
Suzuki S, Satoh T, Yasouka H et al (2005) Novel antibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol 170:141–149
Acknowledgments
This work was supported by the research grant of Jeju National University in 2012.
Conflict of interest
The authors declare that they have no financial or other conflict of interest in relation to this research and its publication.
Ethical standards
This study has been approved by the local ethic committee and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients gave their informed consent prior to their inclusion in the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kang, SY., Oh, JH., Song, S.K. et al. Both binding and blocking antibodies correlate with disease severity in myasthenia gravis. Neurol Sci 36, 1167–1171 (2015). https://doi.org/10.1007/s10072-015-2236-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-015-2236-8